Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 11/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429158 | 1.00 | PIKFYVE (0.66) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL424854 | 0.84 | PIKFYVE (0.64) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL424853 | 0.84 | PIKFYVE (0.64) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL429383 | 0.84 | MAPT (0.59) | PIKFYVEMAPTLMNAKDM4EHPGD | |
| SCHEMBL4120640 | 0.84 | KDM4E (0.59) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL429384 | 0.84 | MAPT (0.59) | PIKFYVEMAPTLMNAKDM4EHPGD | |
| SCHEMBL4120634 | 0.84 | KDM4E (0.59) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL10196514 | 0.81 | SMN1; SMN2 (0.52) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL21135301 | 0.81 | PIKFYVE (0.69) | PIKFYVEGAAMAPTLMNAKDM4E | |
| SCHEMBL24100159 | 0.80 | PIKFYVE (0.68) | PIKFYVEGAAMAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | claimed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | PIKFYVE 3917/4885GAA 688/4885MAPT 1771/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | PIKFYVE 3001/4885GAA 1071/4885MAPT 2861/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | PIKFYVE 1824/4885GAA 2575/4885MAPT 238/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | PIKFYVE 4150/4885GAA 3596/4885MAPT 4316/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | PIKFYVE 4150/4885GAA 3596/4885MAPT 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.